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patients was 14%. There was no evidence of stent migration. 
Conclusion: We observed strut fractures in 13.6% of the nitinol SFA stents at 18 mos. 
mean follow-up. Restenosis defined by arterial duplex doppler occurred in 14% of all 
StentS and in 7% of fractured stents. Fluoroscopic and arterial duplex-doppler follow-up 
of the entire 76 patient cohort (105 stems) is ongoing. Presently, the clinical significance 
of the observed stent fractures is uncertain. 
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Background: With the aim lo establish the long-term value of stenting long superiicial 
femoral artery (SFA) lesions, the data of four German high-volume centers were retro- 
spectively evaluated. 
Methods: Among consecutive SFA stenting procuedures in our centers during 1999- 
2000, 163 SFA stenting procedures using self-expanding nitinol stent (SMART stent, 
Cordis; Group S) were compared with 166 implantation procuedures using self-expand- 
able stainless steel stent (W&tent, Boston Scientific)in the same time window (Group 
W). Patients with in-stent stenting and multiple stent types in the same vessel were 
excluded. 
Results: Patients’ mean age was 66.5+/-10.1 and 32% were females wthout statistically 
significant difference between the two groups. Diabetics included 21% of the S group 
comparing 40% in the W group (p: 0.001). Clinical symptoms based on Rutherford crite- 
na were: (II: S: 19% vs W: lo%, Ill: S:72% vs W:77%, IV: S:5% vs W:lO%, V: S:3% vs 
W:3%; p: NS ). 16% of the Smart group had previous target lesion angioplasty comparing 
23% in the wallstent group (p: NS). There was no difference between the two groups 
comparing lesion length (S: 176+/-110 vs W: 197+/-101 mm p:NS), percent stenosis (S: 
97.9+/-4.6 vs W: 97.2+/-9.9 %) and number of stents (S&W: 1.6+/-l .O). Overall stented 
length was longer in the wallstent group (S: 120+/-76 vs W: 143+/-96 mm, p:O.O4). 
Mean follow-up pertod was 16.9+/-a months. Using Kaplan-Meier analaysis, one-year 
primary patency in the smart group was significantly higher compared to the wallstent 
group (S: 61+/-5% vs W: 30+/-5, p: 0.0000). One-year assisted primary patency 
increased lo 75+1-4% in the S group and 53+/-5% in the W group (p: 0.0000). Secondary 
patency at one-year was 79+/-4% in the S group vs. 64+/-5% in the W group (p: 0.007). 
Conclusion: - Stenting long SFA lesions with nitinol stents is associated wth a signifi- 
cantly better outcome comparing self-expandable stainless steel stents. 
- The long-term secondary patency of about 60% using nitinol stems demonstrates that 
this technology is safe, clinically very effectlve and comparable with reported surgical 
results. 
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Purpose: Renal arlery stenting is safe & efficient but at least 20% of the patients have a 
deterioration of the renal function after the procedure. We evaluate feasibility and safety 
of renal artery angioplasty and stenting using a distal protection device to reduce the risk 
of intraprocedural artery embolism and to avoid deterioration of the renal function. Yeth- 
ods: 46 Hypertensive patients (26 men ; mean age 67.7 + 6.3 years, range (22-67) with 
atherosclerotic renal artery stenosis (6 bilateral) underwent angioplasty & stenting with 
distal protection in 52 renal arteries (46 ostial lesions). 3 patients had solitary kidney, 15 
renal insufficiency. The lesion was crossed either with a Guard Wire temporary occlusion 
balloon (n=36). which was inflated lo provide parenchyma protection or with a filter (EPI 
Filter) fn=l31. Analoauard fn=l) which allow a continuous flow. Generated debris was _ _ 
aspirated and analyzed, blood pressure and serum creatinine levels followed. 
Results: Immediate technical success = 100 %. All lesions exceot 1 were stented. Visi- 
ble debris was aspirated with the Percusurge or removed with filters. Mean particle num- 
ber and diameter = 96.1 * 60.0 per procedure (range 13.206) and 201.2 * 76.0 %m 
(range 36.6206), respectively. Mean renal artery occlusion time = 6.55 * 2.46 mn (range 
2.29-13.21) with the Percusurge Device. Mean time in situ (filters): 4.2 * 1.1 mn. 
Mean follow-up = 23.6 * 14 months (range 1:42). Systolic and diastolic blood pressure 
declined from 169.0 -t 15.1 & 104.0 t 13.0 mm Hg, respectively, lo 149.6 f 12.3 & 92.6 f 
6.7 mm Hg after procedure. The mean cretonne level remains constant during the follow- 
up. At 6 month follow up (31 patients); renal function did not deteriorate in any patient, 
whereas 6 patients with baseline renal insufficiency improved after the procedure. At 3 
years (19 patients) renal function deteriorated only I” 1 patient with renal insufficiency. 
The renal function remains improved in 5 patients. 
Conclusion: These first results suggest the feasibility and safety of distal protection dur- 
ing renal interventions to protect against atheroembolism and to avoid renal function 
deterioration. The beneficial effects should be evaluated by randomized studies. 
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Mintmum stent area (MSA) is a consistent predictor of instent restenosis. In bare metal 
stents (BMS). however, its predictive value is still limited because of biologic variability in 
the restenosis process. The aim of this study was to examine the diagnostic value of 
MSA in prediction of long-term patency of drug-eluting stent (sirolimus-eluting stents, 
SES) implantation compared to BMS. 
Methods: From the SIRIUS trial, 126 (SES 74; BMS 52) cases with complete serial IV&IS 
(baseline and 6 months follow-up) were analysed. MSA at post-procedure and minimum 
lumen area (MLA) at follow-up were obtained. Based on previous physiology studies. 
adequate stent patency at follow-up was defined as MLA > 4.0 mm2. 
Results: In both groups, a significant positive correlation was observed between base- 
line MSA and follow-up MLA (SES: p~O.0001, BMS: pcO.0001). However, SES showed 
higher correlation than BMS (0.60 vs. 0.65) with a higher regression coefficient (0.92 vs. 
0.59). The sensitivity and specificity curves identified different optimal diagnostic thresh- 
olds of MSA for adequate follow-up MLA: 5.0 mn? for SES and 6.5 mm2 for BMS. The 
positive predictive values with these cut-off points were 90% and 56%, respectively. 
Conclusions: Based on the SIRIUS IVUS substudy, in SES, MSA is a stronger predictor 
of outcome than in BMS, due to the reduction of biologic variability. In addition. SES has 
a considerably lower optimal MSA threshold (5.0 mm2) compared to BMS (6.5 mm2). 
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Background: Plaque characteristics may affect pharmacokinetics of drug-eluting stents 
and. therefore. neointimal (NI) orowth suooression. The aim of this studv was to examine 
I _  
the potential influence of plaque calcium (CA) deposits on NI growth following 7.hex- 
anovltaxol-elutino stent (DES) and bare metal stent fBMSI imolantation. 
” ~ , 
Methods: In SCORE, complete 6.month follow-up 3D IVUS data were available in 41 
lesions (DES: 22, BMS: 19). Volume indices (volume/stent length) were computed for 
stem (SVI), lumen (LVI), and neointima (NVI). Lumen and stent contours were extracted 
from the dataset at 0.5 mm intervals over the stented segment. The contours were then 
exporied into custom-designed software lo compute mean NI thickness within 12 
equally-spaced radial sectors in each frame, referenced from the stem center (DES: 
6.040. BMS: 7.224 sectors). The oresence and location of CA deooslt (none: N. suoerfi- 
cial: S, deep: D) were also evaluated at each sector. 
Results: Overall. DES reduced NI orowth cornoared to BMS 10.3iO.3 mmslmm vs 
2.7el.6 mmslmm, pcO.0001). In BMS, larger NI growth was observed at non-calctfied 
plaque segments compared to those with superficial or deep CA. In contrast, with DES 
the NI growth suppression was comparable I” calcified and non-calcified segments (Fig- 
WC?). 
